New drug combo shows promise for aggressive lymphoma in young patients
NCT ID NCT02427620
First seen Nov 21, 2025 · Last updated May 16, 2026 · Updated 24 times
Summary
This study tests whether giving a targeted drug (ibrutinib) plus an immunotherapy (rituximab) before standard chemotherapy can improve outcomes for young patients with newly diagnosed mantle cell lymphoma, an aggressive blood cancer. About 131 participants will receive the combination, followed by consolidation chemotherapy. The main goal is to see how many patients achieve complete or partial remission, while also monitoring side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MANTLE CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.